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OBJECTIVES: During 2009-2011 major healthcare reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the US,
AMNOG in Germany, HSPT in France, KVG in Switzerland and NHS proposed re-
form in the UK. These reforms have major implications on pricing, market access
and HEOR strategy for drug and device products. METHODS: To understand the
implications of these trends, we analyzed 2009-2011 reform bills and proposed
changes worldwide. Additionally, we interviewed public and private payers, key
opinion leaders and payer-influencers to understand implications of these reforms
on drug and device manufacturers. Stakeholders ranked various data collection
methods on a scale of 1-10 (1-least important and 10-most important). RESULTS:
The global healthcare landscape is expected to undergo significant change during
2012-2016. In the US, government will play increased role as a single payer, espe-
cially with–Medicare, Medicaid and CHIP programs– which will cover 114 million
Americans, at a cost of $784 billion. In Germany, AMNOG bill marked the end of free
drug pricing and would lead to increased insurance premiums (now 15.5% of
wages). In the UK, NHS has proposed to replace PCTs with 500-1000 GP-led consor-
tia and use value-based pricing for expensive drugs and devices. Randomized con-
trolled trial, budget impact model and systematic reviews —ranked highest (7.5-
9.1) among payers. Overall, payers view that in the future, health economic
assessments would play critical role in pricing, coverage and reimbursement of
branded products. CONCLUSIONS: This analysis shows that global healthcare
landscape is expected to undergo significant change during 2012-2016. Discussions
with payers, KOLs and payer-influencers highlights increased importance of HEOR
data in the future.
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OBJECTIVES: Estimate the effect size, by means of odds ratios, of explanatory vari-
ables on the reimbursement decision by the Scottish Medicines Consortium (SMC).
METHODS: SMC submissions between 2008-01-01 until 2011-02-01 were reviewed.
From these, 23 a priori defined predictor variables were extracted. Among these
were “BI“ i.e. high and low net budget impact defined as above £500,000, “certainty-
of-ICER“ defined as an ICER (base-case or sensitivity analysis) above £30,000, “com-
parator” defined as active or placebo/uncontrolled trial and “Childhood disease” i.e.
the application is for a childhood disease or not, with childhood defined as below or
above 18 years of age. The impact of these variables was estimated by means of
odds ratios in univariate and multivariate logistic regression analyses. RESULTS:
Two hundred forty-nine drug applications were reviewed; 151 (61%) received a
positive recommendation and 98 (39%) were rejected by SMC. Based on the univar-
iate analyses the following variables were included in the final multivariate model:
“BI“, “certainty-of-ICER “, “comparator” and “Childhood disease”. The other 19 vari-
ables such as chronic use, negative risk profile, type of endpoint and societal im-
pact were excluded during the backward selection process for the multivariate
model. A positive reimbursement was 47.3:1 more likely for “Childhood disease”
versus “no Childhood disease”, 25:1 for certain versus uncertain ICER, 3.33:1 for
active versus placebo/uncontrolled trial and 2.38:1 for low versus high BI. The
corresponding output (OR [95%CI]) from the regression was (47.3[7.1-961.9]) for
“Childhood disease”, (0.04 [0.01-0.11]) for “certainty-of-ICER “, (0.30 [0.11-0.75]) for
“comparator” and (0.42 [0.16-1.10]) for “BI“. The R2 statistic for the multivariate
model was 0.41 and in-sample prediction was 82%. CONCLUSIONS: Most critical
predictors for reimbursement were uncertain ICER and Childhood disease. Future
research should add granularity by also including reimbursement restrictions as
outcome. External validity should be tested by out of sample predictions for new
drugs.
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OBJECTIVES: Since 2005, reimbursement requests for outpatient drugs claiming
added therapeutic value require pharmacoeconomic evidence to obtain reim-
bursement in the The Netherlands. This study aims to obtain insight into the role
of pharmacoeconomics in actual decision making. METHODS: We studied public
reimbursement reports from 2005 onwards and investigated in detail the role of
pharmacoeconomics next to therapeutic value and budget impact in decision
making. RESULTS: From 2005 - April 2011, the Dutch reimbursement agency eval-
uated 304 dossiers, 186 concerned outpatient drugs of which 113 were submitted
with a claim of added therapeutic value. In total, 26 out of 113 were denied reim-
bursement, 60 were classified having added therapeutic value (Annex 1B), 27 were
clustered with equivalent drugs (Annex 1A). Only 30% of the submissions (18 out of
60 positive 1B decisions) contained pharmacoeconomic evidence; 37%, 12% and
22% were exempted due to orphan status, being a HIV drug, or other unknown
reasons, respectively. Three out of the 18 submissions with pharmacoeconomic
evidence only supplied a cost-minimisation analysis, 4 only a cost-effectiveness
analysis (1 alongside a cost-minimisation analysis); 11 supplied a cost-utility anal-
ysis. Uncertainty was often related to (assumed) treatment utilities and the applied
pharmacoeconomic model, only 9 submissions included a cost-effectiveness plane
and an acceptability curve. Interestingly, 4 (2) submissions were judged as “insuf-
ficiently (moderately) founded” pharmacoeconomic evidence but still received a
positive decision, presumably due to their added therapeutic value, treatment mo-
dality, expected budget impact, or orphan status. CONCLUSIONS: Although cost-
effectiveness is a formal reimbursement criterion in the The Netherlands, only 18
out of 60 positively evaluated submissions contained pharmacoeconomic evi-
dence. Only robustness of evidence is evaluated. Even “insufficiently founded”
evaluations can yield positive reimbursement decisions. Hence, cost-effectiveness
does not seem prominent in actual decision making, resulting in uncertainty about
value for money of currently reimbursed drugs.
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WHEN IS LOWER LEVEL EVIDENCE OF EFFECTIVENESS ACCEPTABLE IN
REIMBURSEMENT DECISIONS?: A DECISION ALGORITHM TO GUIDE POLICY
MAKERS
de Groot S1, Rijnsburger A1, Heymans J2, Redekop W1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Dutch Health Care Insurance
Board (CVZ), Diemen, The Netherlands
OBJECTIVES: Reimbursement decisions require evidence of effectiveness and a
randomised controlled trial (RCT) is seen as the best study design to demonstrate
effectiveness. However, there may be situations where a (double-blind) RCT will
not be considered necessary, appropriate, methodologically feasible, or ethical.
The aim of this study was to develop a decision algorithm to determine the appro-
priate level of evidence when assessing the effectiveness of a medical intervention.
METHODS: The initial algorithm was based on the literature and interviews with
personnel at the Health Care Insurance Board (CVZ), the central reimbursement
authority in the The Netherlands. In addition to the results of a previous study of 72
reimbursement dossiers concerning medical specialist care, we also retrospec-
tively studied 20 reimbursement dossiers made by CVZ to identify any arguments
why lower level evidence could be accepted. We then interviewed several Dutch
and foreign experts. Our algorithm was continuously refined during the study and
prospectively validated using new reimbursement dossiers. RESULTS: RCT evi-
dence was lacking in most positive reimbursement decisions (8/9), but also in most
negative reimbursement decisions. Methodological issues can play a role in accept-
ing lower levels of evidence, e.g. when blinding is impossible. Moreover, an RCT
may be unsuitable (e.g. due to time constraints) or viewed as unnecessary (e.g. in
testing parachutes). Finally, ethical reasons can play a role in accepting lower level
evidence. Our decision algorithm contains a stepwise approach to determine the
appropriate evidence level, which includes (double-blind) RCTs, observational
comparative effectiveness research or non-comparative effectiveness research.
CONCLUSIONS: Policy regarding acceptance of lower level evidence in reimburse-
ment decisions needs to be transparent. Our decision algorithm can guide decision
makers in reaching a structured and well-founded decision as to whether lower
level evidence of effectiveness is appropriate.
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OBJECTIVES: Clinical trials (CTs) represent important investments in the clinico-
economic setting, as well as in the “human capital” of developed economies. The
purpose of the study was to depict CT activity in Greece for 2010. METHODS: A
questionnaire-based survey was conducted among the members of the Hellenic
Association of Pharmaceutical Companies (SFEE). Each company was requested to
return via email one questionnaire per interventional CT approved by the Hellenic
National Ethics Committee in the year 2010. Items in the questionnaire focused on
the following points: phase of the trial, duration, number of patients, CT sites,
therapeutic area of the agent under survey and planned budget for the study. The
survey lasted for 4 months (December 2010-March 2011). RESULTS: Fifty of the 65
SFEE members returned questionnaires (response rate 77%). The majority of CTs
was phase-III trials (67%), mainly on oncology (26.5%), endocrine disorders (16.4%)
and cardiovascular diseases (13.9%). Most CT sites were affiliated with a university
(46%) or an NHS hospital (46%), enrolling 4.5-7.5 patients, on average, depending on
CT phase. The average budget per CT was 296,600€ (s.d.: 389,948€). In total, 120
interventional CTs were approved in 2010 in Greece, with the total investment
estimated at 35.6 million Euros. CONCLUSIONS: Compared to its European peers,
the number of CTs conducted in Greece is extremely low. Within a global market
context, this constitutes a problem of lost research opportunities and underuse of
the country’s acknowledged scientific capacity. Major hurdles could be identified in
the “bureaucracy” and complexity of the approval process, mainly within NHS, lack
of acknowledgement of CT as key priority for research investment and lack of a
strong framework for health technology assessment. Quick changes are necessary,
in order to cover the distance lost.
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OBJECTIVES: In the public debate surrounding public health and prevention, it is
sometimes assumed that preventive interventions are by definition cost-effective.
This study aims to explore whether preventive pharmaceutical interventions are
more cost-effective than a curative approach to diseases. METHODS: A descriptive
study identified European economic evaluations in the Tufts Medical Center Cost-
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Effectiveness Analysis Registry between 2000 and 2007. Data were extracted on
publication year, target population, intervention, patient sample, disease, preven-
tion stage, and incremental cost-utility ratio of each economic evaluation. Preven-
tive interventions were defined as measures preventing disease onset. Curative
interventions related to measures identifying patients with risk factors or preclin-
ical disease or interventions limiting disability after harm has occurred. Results
were expressed in terms of costs (valued in 2008 Euro) per quality-adjusted life
year. The association between incremental cost-utility ratios and prevention stage
was examined by means of the Mann-Whitney U-test. RESULTS: The analysis
included 231 studies that reported information about 608 incremental cost-effec-
tiveness ratios. Preventive interventions included interventions that were more
effective and less expensive than comparators (41% of incremental cost-effective-
ness ratios), and interventions that improved outcomes and increased costs (59%).
Both preventive and curative interventions covered the full range of cost-effective-
ness results. However, preventive interventions had a significantly lower median
ratio of 6,255 €per quality-adjusted life year and were thus more cost-effective than
curative interventions (12,917 € per quality-adjusted life year) (p  0.002).
CONCLUSIONS:Although the cost-effectiveness of preventive interventions varies
substantially, preventive interventions tended to be more cost-effective than cu-
rative interventions.
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TENDERING OF BIOSIMILARS IN THE UK – DOES LAUNCH PRICE ACTUALLY
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OBJECTIVES: In the light of the austerity drives and cost containment practices,
payers increasingly resort to procurement procedures in order to award contracts
for the supply of both conventional drugs and biosimilars. The tough reality of
health care economics in conjunction with the commitment of large generic man-
ufacturers, who continue to invest despite the challenges, may mean that tender-
ing of biosimilars may actually be a tool to increase biosimilars’ market share by
demonstrating price competitiveness.This study aims to evaluate how initial list
price, together with other considerations about efficacy and safety, could influence
the hospital formulary inclusion of new biosimilar drugs in the UK. METHODS: A
data framework was developed from secondary research of existing biosimilar list
prices, product profiles, clinical data submitted and current landscape. The frame-
work was validated through phone-based interviews across different regions in the
UK (n10) targeting Hospital procurement Pharmacists in 2011. RESULTS:Majority
of respondents indicated price to be the primary criteria for formulary inclusion
although some pharmacists highlighted efficacy and safety parameters as influ-
encing factorsCONCLUSIONS:The development of clinical commissioning consor-
tia and the expansion of the biosimilar market as major biologicals come off patent
mean that more decisions about biosimilar purchasing could be made jointly with
primary care. Tendering as a mode of procurement for biosimilars, removes the
prescriber’s influence which is the acceptance-limiting step for biosimilars cur-
rently due to the concerns on efficacy and safety. From a hospital procurement
pharmacists’ point of view, it is unclear whether a price discount strategy will
favour the introduction of new biosimilars in the UK hospitals as other factors
might have a more important role in the final purchasing decision.
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OBJECTIVES: Physiotherapy services are reimbursed on a fee for service method in
the ambulatory care in Hungary. The aim of this study is to analyze the utilization
of physiotherapy services in Hungary. METHODS: Data were derived from the fi-
nancial database of the National Health Insurance Fund Administration, the only
health care financing agency in Hungary. We analyzed the year 2008. Medical pro-
cedures which can be performed by physiotherapists were included into the study.
Medical procedures are listed according to the Hungarian version of the Interna-
tional Classification of Procedures in Medicine of WHO. RESULTS: Altogether 151
medical procedures were used by physiotherapists. The following top-11 medical
procedure were responsible for more than half (52.5 %) of total activities: ultra-
sound therapy (8.2 %), iontophorezis (6.5 %), muscle strengthening exercise (4.8 %),
individual training (4.4 %), training for circulation improvement (4.1 %), hand mas-
sage (4.0 %), passive movement of multiple limb (4.0 %), middle frequency treat-
ment (3.8 %), mobilization of joints (3.3 %), exercises against resistance (3.2 %),
education of using medical devices (3.1 %), extension of contracture (3.1 %). Total
annual health insurance reimbursement of physiotherapy services was 7.34 billion
Hungarian Forint (42.7 million USD; 29.2 million EUR). CONCLUSIONS: Physiother-
apy care proved to be a highly concentrated health service where 11 medical pro-
cedures out of 151 are responsible of more than half of activity and health insur-
ance reimbursement.
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OBJECTIVES: ISPOR’s mission is to increase the efficiency, effectiveness, and fair-
ness with which the available health care resources are used to improve health
together with a strong vision be recognized globally as the authority for outcomes
research and its use in health care decisions towards improved health. Despite
modest increases, the membership and conference attendance of health care de-
cision makers still remains low, relative to those involved in academia, industry
and consultancy. Assessing if some of those responsible for utilising HEOR data in
care provision and care practice are aware of ISPOR and its full resources and the
drivers and barriers for involvement could provide an opportunity for increased
membership and active involvement. METHODS: To elucidate the level of aware-
ness of ISPOR, its publications and other resources, interviews were undertaken
with stakeholders within 12 NHS Cancer Networks in the UK. A data framework
was developed to support a series of structured telephone interviews according to
the British Healthcare Business Intelligence (BHBIA) Legal and Ethical Guidelines
for Healthcare Market Research. RESULTS: Spontaneous awareness of ISPOR is
relatively limited within the NHS Cancer Network stakeholders, with even less
awareness to Value in Health. Notable areas of interest were Oncology, Patient Ad-
herence and Persistence and Patient Reported Outcomes Measures. The main bar-
riers to membership of ISPOR was its initial awareness and more effective involve-
ment would be limited due to existing NHS commitments, financial resources and
levels of individual interest /relevance to existing NHS role. Organisational involve-
ment with NHS stakeholder networks would support increased levels of
engagement. CONCLUSIONS: To enhance the awareness of ISPOR, its resources,
conferences and educational support, ISPOR should consider a more targeted
awareness campaign with key NHS clinical networks such as NHS Cancer Net-
works, British Oncology Pharmacy Association and evolving Clinical Commission-
ing Groups.
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OBJECTIVES: Therapeutic monoclonal antibodies (mAbs) are capturing an increas-
ingly larger proportion of the pharmaceutical market. Their specificity for biologi-
cal targets allows them to effectively treat a variety of indications. Yet, despite their
successes, the various stakeholders’ viewpoints in European Union (EU) countries
are often at odds. We explore mAbs as a drug class, specifically, how they are
approved for use by the European Medicines Agency (EMA) and other regulating
bodies and how stakeholders’ opinions diverge from regulatory decisions.
METHODS:The following were summarized for mAbs approved for use in EU coun-
tries from 2000-2011: regulatory approval decisions; comparing and contrasting
payer coverage decisions in selected EU countries; and position statements from
patients, advocacy groups, and medical organizations. Discrepancies between ini-
tial or post-approval regulatory decisions and the statements of the other stake-
holders were highlighted. RESULTS: Nineteen mAbs have been approved by the
EMA during the past 10 years. The summary data show how stakeholders use
clinical data to reinforce their agenda. For instance, bevacizumab has been under-
going battles in both the US and the EU: regulators want to remove specific labeled
indications based on safety and effectiveness data and NICE has advised against
coverage for treating metastatic colorectal cancer, citing inadequate benefits for
the costs, while patients fight for continued access to the therapy to extend their
life at all costs. CONCLUSIONS: After product approval, physicians have tradition-
ally been the key treatment decision makers; however, the influence of other stake-
holders are increasingly affecting the availability and use of drugs. The discordance
between decisions made by regulators and payers has forced drug manufacturers
to not only show that it is safe and efficacious to regulators, but to demonstrate a
product’s value to patients and payers. Incorporating the viewpoints of payers as
well as patients in the drug development process will narrow the gap between
stakeholders.
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OBJECTIVES: Recent increase in competition among hospitals, and managed care,
and the impact of Medicare Prospective Payment System; properly measured hos-
pital performance has become important to evaluate the impact of policies on the
hospital industry. This study assessed the influence of hospital governance on
hospital’s economic performance and efficiency, and it also attempted to system-
atically address the issue of ‘whether participation by insider and outsider busi-
ness community stakeholders on the hospital governing board is related to hospi-
tal’s economic performance’. METHODS: The study was focused on 144
community hospitals in Tennessee; those provided general and acute care services
from 2000 to 2006. An input-oriented and output-oriented Data Envelopment Anal-
ysis (DEA) using multiple input and output variables, which is non-parametric,
flexible, and a mathematical programming approach for the performance assess-
ment, was used to measure the efficiency by estimating the optimum level of
output, conditional upon the mix of inputs. RESULTS: It was found that urban
community hospitals were relatively more efficient than rural community hospi-
tals, and smaller community hospitals were relatively more efficient than their
larger and medium-sized counterparts. Interestingly, the results revealed that
small-sized urban hospitals were relatively more efficient than any other commu-
nity hospital type. From a management and policy perspective type, the study
indicates that both rural and large community hospitals may use urban or small
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